Depressive symptoms and impaired executive functioning, both common in patients with glioblastoma, are independently associated with shorter overall survival.
A core set of symptoms are common across brain tumor patients and underscore the complexity of brain tumors and their management.
New research suggests that characterizing low-grade gliomas according to molecular markers may be a more useful approach in order to guide treatment decisions.
Treating newly diagnosed glioblastoma with “tumor treating fields” is a safe and effective therapeutic option, according to a new trial.
A phase I trial of an oncolytic polio/rhinovirus vaccine was safe and showed promising efficacy in patients with recurrent glioblastoma.
The immunotherapeutic rindopepimut with bevacizumab yielded a significant survival improvement in relapsed glioblastoma patients with a EGFRvIII mutation.
The addition of procarbazine, CCNU, and vincristine to RT in patients with low-grade glioma prolongs progression-free and overall survival vs RT alone.
A combination of bevacizumab and lomustine showed promise in a randomized phase II trial of patients with recurrent glioblastoma, according to study results.
As part of our Society of Neuro-Oncology annual meeting coverage, we discuss quality of life issues and neurologic rehabilitation in patients with neuro-oncologic diseases.